Jonathan W. Friedberg, M.D., M.M.Sc.

Jonathan W. Friedberg, M.D., M.M.Sc.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Administrative: (585) 275-4911
Fax: (585) 273-5761
Office: (585) 275-5823

Professional Bio

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Center, Chief of Hematology/Oncology and Director of Hematological Malignancies Clinical Research.



He is a driving force behind the operations of our clinical programs and a key member of the center's lymphoma Specialized Program of Research Excellence, funded by the National Cancer Institute.

Friedberg is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin's lymphoma.

Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.

His research interests focus on development of novel therapies for patients with lymphoma. Most recently, he was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma, and was selected as a plenary presentation at the annual meeting of the American Society of Hematology.

Awards & Honors (National)

Lawrence A. Kohn Senior Teaching Fellow | Outstanding Teaching Contributions, Department of Medicine, Univ 2004 - 2006

Awards & Honors (Local)

Faculty Academic Mentoring Award | University of Rochester School of Medicine and Dentistry | University of Rochester 2012
Scholar in Clinical Research | Leukemia and Lymphoma Society 2008 - 2008
America's Top Doctors Selection 2008 - 2008
Jacob Gitleman Award | Gilda's Club and Cancer Action | Rochester, NY 2007 - 2007
Clinical Investigator Career Development Award | Lymphoma Research Foundation 2003 - 2003
Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease" | Berlex Oncology Foundation 2001 - 2003
Rising stars program for innovative research | Dunkin Donuts and Dana-Farber Cancer Institute Department of Adu 2001 - 2003

Recent Journal Articles

Showing the 5 most recent journal articles. 80 available »

2013 Apr
Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A. "The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study." Leukemia & lymphoma.. 2013 Apr; 54(4):708-13. Epub 2012 Oct 04.
2012 Oct 1
Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR. "Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study." Cancer.. 2012 Oct 1; 118(19):4842-50. Epub 2012 Mar 20.
2012 Oct 1
Friedberg JW. "Double-hit diffuse large B-cell lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 Oct 1; 30(28):3439-43. Epub 2012 Sep 04.
2012 Sep 20
Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP. "Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 Sep 20; 30(27):3368-75. Epub 2012 Aug 20.
2012 Jun 1
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. "Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database." Cancer.. 2012 Jun 1; 118(11):2944-51. Epub 2011 Oct 17.

Current Appointments

Director - Cancer Center - Primary Administrative
Samuel E. Durand Chair in Medicine - Department of Medicine (SMD)
Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Professor - Cancer Center

Specialties

Internal Medicine - American Board of Internal Medicine
Hematology - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine

Education

MS | Clinical Investigation | Harvard Medical School2001
MD | Medicine | Harvard Medical School1994
BA | Biology | Williams College1990

Post-Doctoral Training & Residency

Fellowship in Hematology/Oncology at Dana-Farber Cancer Institute07/01/1997 - 06/01/1999
Residency in Internal Medicine at Massachusetts General Hospital07/01/1995 - 06/01/1997
Internship in Internal Medicine at Massachusetts General Hospital07/01/1994 - 06/30/1995